Global HIV Vaccine Enterprise steering committees

Enterprise Advisory Group

The Global HIV Vaccine Enterprise Advisory Group (EAG) was established in 2019. It provides strategic and scientific advice on Enterprise activities that best meet the needs of the HIV vaccine research and development field and enable partnerships to deliver on the objectives of the Enterprise.

The EAG is made up of eight to 12 members with deep knowledge of, and strong connections across, the HIV vaccine field. The EAG reflects both gender and geographic diversity and includes civil society and community representatives.

EU Vaccine Reference Group

The EU Vaccine Reference group was established in October 2022. It is made up of around 20 scientists from France, Germany, Italy, Switzerland, Spain, Sweden and other countries.

AIM: Support the development of an HIV vaccine by identifying and addressing barriers to effective R&D at the European level and influence priority settings for the next EU research programme and funding opportunities.

Meet the co-chairs: